Sleeman Lab Publications 2013
Muppala, S., Mudduluru, G., Leupold, J. H., Buergy, D., Sleeman, J.P.* and Allgayer, H.* ,
(2013). CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a. PLoS One, 8:e59563 * Equal contributionSchreiber, C, Kuch, V., Umansky, V. and Sleeman, J. P.
(2013). Autochthonous mouse melanoma and mammary tumors do not express the pluripotency genes Oct4 and Nanog. PLoS One, 8:e57465Kuch, V., Schreiber, C, Thiele, W., Umansky, V. and Sleeman, J. P.
(2013). Tumor initiating properties of breast cancer and melanoma cells in vivo are not invariably reflected by spheroid formation in vitro, but can be increased by long-term culturing as adherent monolayers. Int. J. Cancer, 132:E94-105 2012Sleeman, J.P., Cady, B., and Pantel, K.
(2012). The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications. Clin. Exp. Metastasis, 29:737-746Thiele, W., Krishnan, J., Rothley, M., Weih, D., Plaumann, D., Kuch, V., Quagliata, L., Weich, H. and Sleeman, J. P.
(2012). VEGFR-3 is expressed on megakaryocyte precursors in the murine bone marrow and plays a regulatory role in megakaryopoiesis. Blood, 120:1899-1907.Sleeman, J.P.
(2012). The metastatic niche and stromal progression. Cancer and Metastasis Reviews, 31:429-440Sleeman, J.P., Christofori, G., Fodde, R., Collard, J., Berx, G., Decraene, C. and Rüegg, C.
(2012). Concepts of metastasis in flux: the stromal progression model. Seminars in Cancer Biology, 22:174-186Sleeman, J.P.
(2012). Metastasis: Understanding is the beginning of order in chaos. Seminars in Cancer Biology, 22:173Thaler, S., Schad, A., Schmidt, M. and Sleeman, J.P.
(2012). RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signaling: implications for breast cancer development. Oncogene, 31: 4912-22Neeb, A., Wallbaum, S., Novac, N., Scholl, I., Dukovic-Schulze, S., Schreiber, C., Schlag, P., Moll, J., Stein, U. and Sleeman, J. P.
(2012). The immediate early gene Ier2 promotes tumor cell motility and metastasis, and predicts poor survival of colorectal carcinoma patients. Oncogene, 31:3796-3806Baumann, P., Thiele, W., Cremers, N., Muppala, S., Krachulec, J., Diefenbacher, M., Kassel, O., Mudduluru, G., Allgayer, H., Frame, M. and Sleeman, J. P.
(2012). CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci., 69: 435-448Lukanidin, E. and Sleeman, J.P.
(2012). Building the niche: The role of the S100 proteins in metastatic growth. Seminars in Cancer Biology, 22:216-225Kaindl, T., Rieger, H., Kaschel, L., Engel, U., Schmaus, A., Sleeman, J.P.* and Tanaka, M.*
(2012). Spatio-temporal patterns of pancreatic cancer cells expressing CD44 isoforms on supported membranes displaying hyaluronic acid oligomers arrayed with a defined distribution. PLoS One, 7: e42991 * Equal contributionBack to top
2011
Rana S, Claas C, Kretz CC, Nazarenko I, Zoeller M.
(2011). Activation-induced internalization differs for the tetraspanins CD9 and Tspan8: Impact on tumor cell motility. Int J Biochem Cell Biol. 43:106-19Geyer FL, Ueda E, Liebel U, Grau N and Levkin PA.
(2011). Superhydrophobic-Superhydrophilic Micropatterning: Towards Genome-on-a-Chip Cell Microarrays. Angew Chem Int Ed Engl. doi: 10.1002/anie.201102545Thaler, S., Schad, A., Schmidt, M. and Sleeman, J.P.
(2011). RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signaling: implications for breast cancer development. Oncogene, in pressBaumann, P., Thiele, W., Diefenbacher, M., Kassel, O., Frame, M. and Sleeman, J.P.
(2011). CD24 interacts with and promotes the activity of c-src in the context of lipid rafts, thereby increasing the kinetics of integrin-dependent cell adhesion, spreading and focal adhesion formation. Cell Mol Life Sci., Epub ahead of printNeeb, A., Wallbaum, S., Novac, N., Scholl, I., Dukovic-Schulze, S., Schreiber, C., Schlag, P., Moll, J., Stein, U. and Sleeman, J. P.
(2011). The immediate early gene Ier2 promotes tumor cell motility and metastasis, and predicts poor survival of colorectal carcinoma patients. Oncogene, doi: 10.1038/onc.2011.535Sleeman, J.P., Nazarenko, I. and Thiele, W.
(2011). Do all roads lead to Rome? Routes to metastasis development. Int. J. Cancer, 128: 2511-26Witte, M.H., Dellinger, M.T., McDonald, D.M., Nathanson, S.D., Boccardo, F.M., Campisi, C.C.C., Sleeman, J.P. and Gershenwald, J.E.
(2011). Lymphangiogenesis and Hemangiogenesis: Potential Targets for Therapy. J. Surg. Oncol., 103: 489-500Sleeman, J.P. and Thiery, J.P.
(2011). The epithelial-mesenchymal transition. Cell 145: 162.e1Devitt-Moller, H., Ralfkjaer, U., Cremers, N., Frankel, M., Troelsgaard Pedersen, R., Klingelhöfer, J., Yanashigawa, H., Grigorian, M., Guldberg, P., Sleeman, J. P., Lukanidin, U. and Ambartsumian, N.
(2011). Role of Fibulin-5 (FBLN5) in late stage metastasogenesis. Molecular Cancer Research, 9: 553-63Thiele, W., Novac, N., Mink, S., Schreiber, C., Plaumann, D., Fritzmann, J., Schwager, C., Regiert, T., Huber, P. E., Stein, U., Schlag, P., Moll, J., Abdollahi, A. and Sleeman, J.P.
(2011). Discovery of a novel tumor metastasis-promoting gene NVM-1. J. Pathol., 225: 96-105Kaufmann L, Marinescu G, Nazarenko I, Thiele W, Oberle C, Sleeman J and Blattner C.
(2011). LiCl induces TNF-alpha and FasL production, thereby stimulating apoptosis in cancer cells. Cell Communication and Signalling, 9: 15.Back to top
2010
Virlouvet, M., Gartner, M., Koroniak, K., Sleeman, J.P., and Bräse, S.
(2010). Multi-Gram Synthesis of a Hyaluronic Acid Subunit and Synthesis of Fully Protected Oligomers. Advanced Synthesis & Catalysis, 352: 2657-2662.Cremers, N and Sleeman, J.P.
(2010) Loss of CD24 expression promotes ductal branching and enhanced alveoli formation in the murine mammary gland. Cell Mol Life Sci., 67: 2311-2322Sleeman, J. P. and Steeg, P. S.
(2010) Cancer metastasis as a therapeutic target. European J. Cancer, 46: 1177-1180Müller, T., Stein, U., Poletti, A., Garzia, L., Rothley, M., Plaumann, D., Thiele, W., Bauer, M., Galasso, A., Schlag, P., Pankratz, M., Zollo, M. and Sleeman, J. P.
(2010). ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and correlates with poor survival in colorectal cancer patients. Oncogene, 29: 2393-2403Sleeman, J. P.
(2010). Understanding the mechanisms of lymphangiogenesis: a hope for cancer therapy? Phlebolymphology, 17: 99-107Gebhardt, C., Averbeck, M., Diedenhofen, N., Willenberg, A., Anderegg, U., Sleeman, J.P. and Simon, J.C.
(2010). Dermal hyaluronan is rapidly reduced by topical treatment with glucocorticoids. J. Invest. Dermatol., 130: 141–149Back to top
2009
Thaler S, Hähnel PS, Schad A, Dammann R, Schuler M.
(2009). RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res., 69(5):1748-57Teller, N., Thiele, W., Boettler, U., Sleeman, J. P. and Marko, D.
(2009). Delphinidin inhibits a broad spectrum of receptor tyrosine kinases of the ErbB and VEGFR family. Mol. Nutrition & Food Res., 53: 1075 - 1083Sleeman, J. P. and Thiele, W.
(2009). Tumor metastasis and the lymphatic vasculature. Int. J. Cancer, 125: 2747 - 2756Sleeman, J. P., Schmid A. and Thiele, W.
(2009). Tumor lymphatics. Semin. Cancer Biol. 19: 285 - 297Steeg, P. S., Anderson, R. L., Bar-Eli, M., Chambers, A. F., Eccles, S. A., Hunter, K., Itoh, K., Kang, Y., Matrisian, L. M., Sleeman, J. P., Theodorescu, D., Thompson, E. W. and Welch, D. R.
(2009). Preclinical drug development must consider the impact on metastasis. Clin. Cancer Res., 15: 4529-4530Teller, N., Thiele, W., Marczylo, T, Gescher, A., Boettler, U., Sleeman, J. P. and Marko, D.
(2009). Suppression of the kinase activity of receptor tyrosine kinases by anthocyanin mixtures extracted from bilberries and grapes. J. Agricultural and Food Chem., 57: 3094-3101.Wallbaum, S., Grau, N., Schmid, A., Frick, K., Neeb, A. and Sleeman, J.P.
(2009). Cell cycle quiescence suppresses transcription from an ecdysone receptor-based inducible promoter in mammalian cells. Biotechniques 46: 433 - 440Rothley., M, Thiele, W., Schacht, V., Plaumann, D., Gartner, M., Giannis, A. and Sleeman, J.P.
(2009). Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo. Int. J. Cancer 125: 34 - 42Sleeman, J.P. and Neeb, A.
(2009). Chapter 12. Tumor Lymphangiogenesis: What We Know and Don't Know. In From Local Invasion to Metastatic Cancer: Involvement of Distant Sites through the Lymphovascular System. Editor: Stanley P. L. Leong, M.D. Publisher: Springer. In pressAnderegg, U., Eichenberg, T., Parthaune, T., Haiduk, C., Saalbach, A., Milkova, L., Ludwig, A., Grosche, J., Averbeck, M., Gebhardt, C., Voelcker, V., Sleeman, J.P. and Simon J.C.
(2009). ADAM10 Is the Constitutive Functional Sheddase of CD44 in Human Melanoma Cells. J Invest Dermatol. 129:1471-1482Back to top
2008
Voelcker, V., Gebhardt, C., Averbeck, M., Saalbach, A., Wolf, V., Weih, F., Sleeman, J. P., Anderegg, U. and Simon, J. C.
(2008). Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells through TLR4. Exp. Dermatol. 17: 100-107.Bruyère F, Melen-Lamalle L, Blacher S, Roland G, Thiry M, Moons L, Frankenne F, Carmeliet P, Alitalo K, Libert C, Sleeman JP, Foidart JM, Noël A.
(2008). Modeling lymphangiogenesis in a three-dimensional culture system. Nat Methods 5: 431-437.Back to top
2007
Sleeman, J.P. and Cremers, N.
(2007). New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment. Clinical and Experimental Metastasis 24: 707-715Eccles, S., Paon, L. and Sleeman, J.P.
(2007). Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clinical and Experimental Metastasis 24: 619-636Berx, G., Raspé, E., Christofori, G., Thiery, J.P. and Sleeman, J.P.
(2007). Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clinical and Experimental Metastasis, 24: 587-597Sleeman, J.P.
(2007) The relationship between tumors and the lymphatics: consequences for metastasis. In: Tumor Angiogenesis, (Fusenig, N. and Marmé, D, Eds), Springer Verlag.Averbeck, M., Gebhardt, C., Anderegg, U., Termeer, C., Sleeman, J.P. and Simon, J. C.
(2007) Switch of Syndecan-1 and Syndecan-4 expression controls maturation-associated dendritic cell motility. Exp. Dermatol., 16: 580-589.Averbeck, M., Gebhardt C., Voigt S., Beilharz S., Anderegg U., Termeer C., Sleeman, J. P. and Simon, J. C.
(2007) Differential regulation of hyaluronan metabolism in the epidermal and dermal compartments of human skin by UVB irradiation. J. Invest. Dermatol., 127: 687-697Saalbach, A., Klein, C., Sack, U., Anderegg, U., Kauer, F., Gebhardt, C., Averbeck, M., Sleeman, J. P. and Simon, J. C.
(2007) Dermal fibroblasts induce maturation of dendritic cells. J.Immunology, 178: 4966-4974.Back to top
2000 – 2006
Sleeman, J. P.
(2006). The relationship between tumors and the lymphatics: what more is there to know? Lymphology, 39: 62-68.Thiele, W. and Sleeman, J. P.
(2006). Tumor-induced lymphangiogenesis: a target for cancer therapy? J. Biotechnology, 124: 224-241.Thiery, J. P. and Sleeman, J. P.
(2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology, 7: 131-142Baumann, P., Cremers, N., Kroese, F., Orend, G., Chiquet-Ehrismann, R., Uede, T., Yagita, H. and Sleeman, J. P.
(2005). CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Research, 65: 10783-10793Schempp, C. M., Kiss, J., Kirkin, V., Simon-Haarhaus, B., Kremer, B., Termeer, C., Sleeman, J. P. and Simon, J. C.
(2005). Hyperforin acts as an angiogenesis inhibitor in vitro and in vivo. Planta Medica, 71: 999-1004Gartner M., Müller T., Simon J.C., Giannis A., Sleeman J.P.
(2005). Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent. Chembiochem, 6, 171-177.Kirkin V., Thiele W., Baumann P., Mazitschek R., Rohde K., Fellbrich G., Weich H., Waltenberger J., Giannis A., Sleeman J.P.
(2004). MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int. J. Cancer, 112, 986-993.Mengwasser J., Piau A., Schlag P., Sleeman J.P.
(2004). Differential immunization identifies PHB1/PHB2 as blood-borne tumor antigens. Oncogene, 23, 7430-7435.Bando H., Brokelmann M., Toi M., Alitalo K., Sleeman J.P., Sipos B., Grone H.J., Weich H.A.
(2004). Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. Int. J. Cancer, 111, 184-191.Fieber, C., Baumann, P., Vallon, R., Hofmann, M., Angel, P., Herrlich, P. and Sleeman, J. P.
(2004). Hyaluron-oligosaccharide-induced transcription of metalloproteases. J. Cell Sci., 117, 359-367.Van Trappen, P. O., Steele, D., Lowe, D. G., Baithun, S., Levey, P., Beasley, N., Thiele, W., Weich, H., Krishnan, J., Shepherd, J. H., Pepper, M. S., Jackson, D., Sleeman, J. P. and Jacobs, I. J.
(2003). Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J. Pathol., 201, 544-554.Bosserhoff, A.-K., Stoll, R., Sleeman, J. P., Bataille, F., Buettner, R. and Holak, T. A.
(2003). Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of MIA (melanoma inhibitory activity). Lab. Invest., 83, 1583-1594.Termeer, C., Voith, U., Hara, M., Eibel, H., Sleeman, J. P. and Simon, J. C.
(2003). Targeting dendritic cells with CD44 monoclonal antibodies selectively inhibits the proliferation of naive CD4+ T-helper cells by induction of FAS independent T-cell apoptotsis. Immunology, 109, 32-40.Tille, J. C., Wang, X., Lipson, K. E., McMahon, G., Ferrara, N., Zhu, Z., Hicklin, D. J., Sleeman, J. P., Eriksson, U., Alitalo, K. and Pepper, M. S.
(2003). Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-CΔNΔC- and VEGF-A-induced angiogenesis in vitro. Exp. Cell Res., 285, 286-298.Termeer, C., Sleeman, J. P. and Simon, J. C.
(2003). Hyaluronan - magic glue for the regulation of the immune response? Trends in Immunology, 24, 112-114.Krishnan, J., Kirkin, V., Steffen, A., Hegen, M., Weih, D., Tomarev, S., Wilting, J. and Sleeman, J. P.
(2003). Differential in vivo and in vitro expression of VEGF-C and VEGF-D in tumors and its relationship to lymphatic metatasis in immunocompetent rats. Cancer Research, 63, 713-722.Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P. and Ponta, H.
(2002). Requirement for CD44 in two subsequent steps of HGF/c-Met signaling. Genes and Development, 16, 3087-3099.Khaldoyanidi, S., Karakhanova, S., Sleeman, J.P., Herrlich, P. and Ponta, H.
(2002). CD44 variant specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages. Blood, 99, 3955-3961.Sleeman, J. P., Baumann, P., Novac, N., Thies, W.-G., Nestl, A., von Stein, O. and Hofmann, M.
(2002). Genetik der Tumormetastasen. FZK Nachrichten, 34, 31-35.Mengwasser J., Liu F.T., Sleeman J.P.
(2002). Expression of Galectin-3 is strongly upregulated in non-apoptosing mammary epithelial cells during rat mammary gland involution. Glycobiology, 12, 129-134.Schempp, C., Kirkin, V., Simon-Haarhaus, B., Kersten, A., Termeer, C., Gilb, B., Sleeman, J.P. and Simon, J.
(2002). Inhibition of tumor growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene, 21, 1242-1250.Göttlicher, M., Minucci, S., Zhu, P., Krämer, O., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. and Heinzel, T.
(2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 20, 6969-6978.Sleeman, J. P.
(2001). Wie sicher ist genetisch verändertes Getreide? Naturschutzblätter, in press.Kirkin, V., Mazitschek, R., Krishnan, J., Steffen, A., Waltenberger, J., Pepper, M.S., Giannis, A. and Sleeman, J.P.
(2001). Characterisation of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. European Journal of Biochemistry, 268, 5530-5540.Papoutsi, M., Sleeman, J.P., Wilting, J.
(2001). Interaction of rat tumor cells with blood vessels and lymphatics of the avian chorioallantoic membrane. Microscopy Research and Technique, 55, 100-107.Sleeman, J.P., Krishnan, J., Kirkin, V. and Baumann, P.
(2001). Markers for the lymphatic endothelium: in search of the Holy Grail? Microscopy Research and Technique, 55, 61-69.Sleeman, J. P., Novac, N., Thies, W.-G., Nestl, A., von Stein, O. and Hofmann, M.
(2001). Molecular and cellular mechanisms of lymphogenic metastatic spread: underlying changes in gene expression patterns. In Proceedings of the 4th International Symposium on Metastases in Head and Neck Cancer: Advances in Experimental and Clinical Research (Ed. Werner, J.), pp 93-97.Mengwasser, J. and Sleeman, J. P.
(2001). Expression of M-N#1, a histo-blood group B-like antigen, is strongly upregulated in non-apoptosing mammary epithelial cells during rat mammary gland involution. Glycobiology, 11, 441-449.Ahrens, T., Sleeman, J.P., Schempp, C.M., Howells, N., Hofmann, M., Ponta, H., Herrlich, P., Simon, J.C.
(2001). Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene, 20, 3399-3408.Sleeman, J. P., Thies, W.-G., Nestl, A., von Stein, O. and Hofmann, M.
(2001). Fact and Fiction: changing concepts in tumor metastasis. In The Sentinel Lymph Node Concept in Oncology - Facts and Fiction (Ed. Munz, D.). W. Zuckschwerdt Verlag, Berlin, pp 13-25Nestl, A., Von Stein, O., Zatloukal, K., Thies, W.-G., Herrlich, P., Hofmann, M. and Sleeman, J. P.
(2001). Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Research, 61, 1569-1577.Herrlich, P., Morrison, H., Sleeman, J. P., Orian-Rousseau, V., König, H., Weg-Remmers, S. and Ponta, H.
(2000). CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-supressing cofactor. Annals N. Y. Acad. Sci., 910, 106-120.Hebbard, L., Steffen, A., Zawadski, V., Fieber, C., Howells, N., Moll, J., Ponta, H., Hofmann, M., and Sleeman, J.P.
(2000). CD44v6 expression and regulation during mammary gland development and function: implications for mammary carcinogenesis. J. Cell Science, 113, 2619-2630.Sleeman, J.P.
(2000). The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results in Cancer Research, 157, 55-81.Back to top
Pre 2000
Sherman, L., Sleeman, J.P., Hennigan, R., Herrlich, P. and Ratner, N.
(1999). Overexpression of activated neu/erbB2 initiates immortalisation and malignant transformation of immature schwann cells in vitro. Oncogene, 18, 6692-6699.Sleeman, J.P., Kim, U., LePendu, J., Coquerelle, T., Ponta, P. and Herrlich, P.
(1999). Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B. Oncogene, 18, 4485-4494.Fieber, C., Plug, R., Sleeman, J.P., Dall, P., Ponta, H. and Herrlich, P.
(1999). Characterization of the murine gene encoding the intracellular hyaluronan receptor IHABP (RHAMM). Gene, 226, 41-50.Katagiri, Y., Sleeman, J.P., Fujii, H., Herrlich, P., Tanaka, K., Ijima, K., Murakami, M., Saiki, I., Chambers, A. and Uede, T.
(1999). Enhancement of cell binding to osteopontin through CD44-mediated signalling in RGD-independent and beta 1 Integrin-dependent manner. Cancer Res., 59, 219-226.Hofmann, M., Assmann, V., Fieber, C., Sleeman, J.P., Moll, J., Ponta, H., Hart, I. R. and Herrlich, P.
(1998). Problems with RHAMM: a new link between surface adhesion and oncogenesis. Cell, 95, 591-592.Herrlich, P., Sleeman, J.P., Wainwright, D., König, H., Sherman, L., Hilberg, F. and Ponta, H.
(1998). How tumor cells make use of CD44. Cell Adhesion and Communication, 6, 141-147.Weiss, J. M., Renkl, A. C., Sleeman, J.P., Dittmar, H., Termeer, C., Taxis, S., Howells, N., Schöpf, E., Ponta, H., Herrlich P. and Simon, J. C.
(1998). CD44 variant isoforms are essential for the function of epidermal Langerhans cells and dendritic cells. Cell Adhesion and Communication, 6, 157-160.Moll., J., Khaldoianidi, S., Sleeman, J.P., Preuss, I., Ponta, H. and Herrlich, P.
(1998). Two different roles for CD44 proteins in human myelopoiesis. J. Clin. Invest., 102, 1024-1034Sleeman, J.P., Rahmsdorf, U., Stefan, A., Ponta, H. and Herrlich, P.
(1998). CD44 exon v5 encodes a tyrosine which is sulfated. Eur. J. Biochem., 255, 74-80.Gao, A., Lou, W., Sleeman, J.P. and Isaacs, J.
(1998). Metastasis suppression by the standard CD44 isoform does not require binding of prostate cells to hyaluronate. Cancer Research, 58, 2350-2352.Hofmann, M., Fieber, C., Assmann, V., Göttlicher, M., Sleeman, J.P., Plug, R., Howells, N., von Stein, O., Ponta, H. and Herrlich, P.
(1998). Identification of IHABP, a 95kD intracellular hyaluronate binding protein. J. Cel.l Sci., 111, 1673-1684.Amaravadi, L.S., Neff, A.W., Sleeman, J.P. and Smith, R.C.
(1997). Autonomous neural axis formation by ectopic expression of the protooncogene c-ski. Dev. Biol., 192, 392-404.Sleeman, J.P., Kondo, K., Moll, J., Ponta, H. and Herrlich, P.
(1997). CD44 variant exons v6 and v7 together extend the repertoire of glycosaminoglycans bound by CD44. J. Biol. Chem., 272, 31837-31844.Sleeman, J.P.
(1997). Blood group antigen expression during metastasis and active cell death. FZK Nachrichten, 29 3/97, 241-243.Weiss, J. M., Sleeman, J.P., Renkl, A. C., Termeer, C., Dittmar, H., Taxis, S., Howells, N., Hofmann, M., Schöpf, E., Ponta, H., Herrlich P. and Simon, J. C.
(1997). An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. J. Cell Biol., 137, 1137-1147.Sleeman, J.P., Rudy, W., Hofmann, M., Moll, J., Ponta, P. and Herrlich, P.
(1996). Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. J. Cell Biol., 135, 1139-1150.Sleeman, J.P., Arming, S., Moll, J., Hekele, A., Rudy, W., Hofmann, M., Kreil, G., Ponta, H. and Herrlich, P.
(1996). Metastasis associated variants of CD44 bind to hyaluronic acid, but this binding is not required for their metastasis-conferring abilities. Cancer Research, 56, 3134-3141.Sherman, L., Sleeman, J.P., Dall, P., Moll, J., Ponta, H. and Herrlich, P.
(1996). The CD44 proteins in embryonic development and cancer. Current Topics in Microbiology and Immunology, 213, 249-269.Wainwright, D., Sherman, S., Sleeman, J.P., Ponta, H. and Herrlich, P.
(1996). A splice variant of CD44 expressed in the rat apical ectodermal ridge contributes to limb outgrowth. Ann. N. Y. Acad. Sci., 785, 345-349.Sleeman, J.P.
(1995). The stay abroad. In Training and mobility of researchers in Europe - politics and practice , p185-186. DLR e.v., Bonn, Germany.Ponta, H., Sleeman, J.P., Dall, P., Moll, J., Sherman, L. and Herrlich, P.
(1995). CD44 isoforms in metastatic cancer. Invasion Metastasis, 14, 82-86.Hudson, D., Sleeman, J.P. and Watt, F.
(1995). CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratinocytes and plays a role in intercellular adhesion. J. Cell Sci., 108, 1959-1970.Sleeman, J.P., Moll, J., Sherman, L., Dall, P., Pals, T., Ponta, H. and Herrlich, P.
(1995). The role of CD44 splice variants in human metastatic cancer. Ciba Foundation Symp. 189, 142-156. John Wiley and Sons, Chichester, England.Moll, J., Sleeman, J.P., Kondo, K., Hekele, A., Plug, R., Sherman, L., Ponta, H., Herrlich, P., Schmidt, A., Zöller, M., Horst, E. and Pals, S.
(1994). Analysis of molecular functions of the tumour metastasis promoting surface molecule CD44v4-v7 using transgenic mice. Proc. 24th Int. Symp. Princess Takamatsu Cancer Res. Fund, p142-151.Sherman, L., Sleeman, J.P., Herrlich, P. and Ponta, H.
(1994). Hyaluronate receptors: key players in growth, differentiation, migration and tumour progression. Curr. Op. Cell Biology, 6, 726-733.Ponta, H., Sleeman, J.P. and Herrlich, H.
(1994). Tumour metastasis formation: cell surface properties confer metastasis-promoting or suppressing properties. Biochim. Biophys. Acta, 1198, 1-10.Herrlich, P., Rudy, R., Hofmann, M., Arch, R., Zöller, M., Zawadski, V., Tölg, C., Hekele, A., Pals, S., Heider, K.-H., Sleeman, J.P. and Ponta, H.
(1993). CD44 and splice variants of CD44 in normal differentiation and tumour progression. In Cell Adhesion Molecules (eds. M. Hemler and E. Mihich), p265-288. Plenum Press.Sleeman, J.P.
(1993). Xenopus A-myb is expressed during early spermatogenesis. Oncogene, 8, 1931-1941.Sleeman, J.P. and Laskey, R.A.
(1993). Xenopus c-ski contains a novel coiled-coil protein domain, and is maternally expressed during development. Oncogene, 8, 67-77.Sleeman, J.P.
(1992). Nuclear Oncogenes, Cancer and the Growth Control Network. In Introduction to the Molecular Genetics of Cancer (ed. R. Vile), p72-98. John Wiley & Sons Ltd.Burnett, T.S., and Sleeman, J.P.
(1984). Uneven distribution of methylation sites within the human papillomavirus 1a genome: possible relevance to viral gene expression. Nucleic Acids Research, 12, 8844-8860.Back to top